In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
Biobased sunglasses assist British special forces team with record-breaking Everest trek
In Nepal, four former British special forces soldiers were outfitted with bioplastic sunglasses from Teysha Technologies as they set a mountaineering record for traveling...
Diaper duty development: Hiro unveils nappy-eating fungi
In Texas, a startup has introduced a new diaper concept that aims to address one of the biggest challenges parents face: balancing sustainability with...
von Holzhausen creates “Ripple shoe” from proprietary renewable material
In California, sustainable material firm von Holzhausen has made a 100% biodegradable and plastic-free shoe from Liquidplant™, a polyurethane-like material developed in house out...